February 12, 2018 — Philips is recalling the HeartStart MRx Defibrillator due to a defect in the device's Gas Discharge ...

Fox Business News recently featured GE Healthcare’s ultrasound technologies in a 6-minute segment with the Innovations ...

February 8, 2018 – Calgary Scientific announced a renewed focus on an enterprise cloud strategy, which will support its ...

Medtronic plc recently added to its body of clinical evidence supporting the In.Pact Admiral drug-coated balloon (DCB) with new presentations that demonstrated durable and consistent clinical outcomes in peripheral artery disease (PAD). The new data, presented at the Leipzig Interventional Course (LINC), Jan. 30-Feb. 2, 2018, in Leipzig, Germany, included the two-year results from the MDT-2113 study (IN.PACT SFA Japan) and data from a critical limb ischemia (CLI) subgroup analysis from the IN.PACT Global Study.

High exposure to radiofrequency radiation (RFR) in rodents resulted in tumors in tissues surrounding nerves in the hearts of male rats, but not female rats or any mice, according to draft studies from the National Toxicology Program (NTP). The exposure levels used in the studies were equal to and higher than the highest level permitted for local tissue exposure in cell phone emissions today. Cell phones typically emit lower levels of RFR than the maximum level allowed. NTP’s draft conclusions were released as two technical reports, one for rat studies and one for mouse studies. NTP will hold an external expert review of its complete findings from these rodent studies March 26-28.